Clinical Treatment for Covid-19 - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510244189

Publication Date:

October 29, 2024

Pages:

165

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

IT Services [2]

Hardware (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

Clinical Treatment for Covid-19 refers to the medical interventions and therapies provided to individuals diagnosed with the disease. These treatments can include oxygen therapy, antiviral medications, anti-inflammatory drugs, and in severe cases, mechanical ventilation and ECMO support. The specific treatment plan varies based on the severity of symptoms, patient health, and medical guidelines.
The global market for Clinical Treatment for Covid-19 was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Clinical Treatment for Covid-19, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Clinical Treatment for Covid-19 by region & country, by Type, and by Application.
The Clinical Treatment for Covid-19 market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Clinical Treatment for Covid-19.
麻豆原创 Segmentation
By Company
Applied DNA Sciences, Inc
Codagenix
GeoVax Labs, Inc.
Takis Biotech
Evvivax
Zydus Cadila
MIGAL Galilee Research Institute
Generex Biotechnology Corporation
Moderna Therapeutics
Novavax
Bravovax
Ascletis Pharma
Janssen Pharmaceuticals
Altimmune
Greffex Inc.
CanSino Biologics, Inc.
ExpreS2ion Biotechnologies ApS
Clover Biopharmaceuticals
Vaxil Bio Ltd.
iBio Pharma Inc
Tonix Pharmaceuticals
Curevac
ImmunoPrecise
Segment by Type:
Antimicrobial Therapy
Renal Failure and Renal Replacement Therapy
Lung Replacement Therapy
Immunotherapy
Others
Segment by Application
Children
Adult
Special Groups
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Clinical Treatment for Covid-19 manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Clinical Treatment for Covid-19 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Clinical Treatment for Covid-19 in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Clinical Treatment for Covid-19 Product Introduction
1.2 Global Clinical Treatment for Covid-19 麻豆原创 Size Forecast
1.3 Clinical Treatment for Covid-19 麻豆原创 Trends & Drivers
1.3.1 Clinical Treatment for Covid-19 Industry Trends
1.3.2 Clinical Treatment for Covid-19 麻豆原创 Drivers & Opportunity
1.3.3 Clinical Treatment for Covid-19 麻豆原创 Challenges
1.3.4 Clinical Treatment for Covid-19 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Clinical Treatment for Covid-19 Players Revenue Ranking (2023)
2.2 Global Clinical Treatment for Covid-19 Revenue by Company (2019-2024)
2.3 Key Companies Clinical Treatment for Covid-19 Manufacturing Base Distribution and Headquarters
2.4 Key Companies Clinical Treatment for Covid-19 Product Offered
2.5 Key Companies Time to Begin Mass Production of Clinical Treatment for Covid-19
2.6 Clinical Treatment for Covid-19 麻豆原创 Competitive Analysis
2.6.1 Clinical Treatment for Covid-19 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Clinical Treatment for Covid-19 Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Clinical Treatment for Covid-19 as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Antimicrobial Therapy
3.1.2 Renal Failure and Renal Replacement Therapy
3.1.3 Lung Replacement Therapy
3.1.4 Immunotherapy
3.1.5 Others
3.2 Global Clinical Treatment for Covid-19 Sales Value by Type
3.2.1 Global Clinical Treatment for Covid-19 Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Clinical Treatment for Covid-19 Sales Value, by Type (2019-2030)
3.2.3 Global Clinical Treatment for Covid-19 Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Children
4.1.2 Adult
4.1.3 Special Groups
4.2 Global Clinical Treatment for Covid-19 Sales Value by Application
4.2.1 Global Clinical Treatment for Covid-19 Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Clinical Treatment for Covid-19 Sales Value, by Application (2019-2030)
4.2.3 Global Clinical Treatment for Covid-19 Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Clinical Treatment for Covid-19 Sales Value by Region
5.1.1 Global Clinical Treatment for Covid-19 Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Clinical Treatment for Covid-19 Sales Value by Region (2019-2024)
5.1.3 Global Clinical Treatment for Covid-19 Sales Value by Region (2025-2030)
5.1.4 Global Clinical Treatment for Covid-19 Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Clinical Treatment for Covid-19 Sales Value, 2019-2030
5.2.2 North America Clinical Treatment for Covid-19 Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Clinical Treatment for Covid-19 Sales Value, 2019-2030
5.3.2 Europe Clinical Treatment for Covid-19 Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Clinical Treatment for Covid-19 Sales Value, 2019-2030
5.4.2 Asia Pacific Clinical Treatment for Covid-19 Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Clinical Treatment for Covid-19 Sales Value, 2019-2030
5.5.2 South America Clinical Treatment for Covid-19 Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Clinical Treatment for Covid-19 Sales Value, 2019-2030
5.6.2 Middle East & Africa Clinical Treatment for Covid-19 Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Clinical Treatment for Covid-19 Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Clinical Treatment for Covid-19 Sales Value
6.3 United States
6.3.1 United States Clinical Treatment for Covid-19 Sales Value, 2019-2030
6.3.2 United States Clinical Treatment for Covid-19 Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Clinical Treatment for Covid-19 Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Clinical Treatment for Covid-19 Sales Value, 2019-2030
6.4.2 Europe Clinical Treatment for Covid-19 Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Clinical Treatment for Covid-19 Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Clinical Treatment for Covid-19 Sales Value, 2019-2030
6.5.2 China Clinical Treatment for Covid-19 Sales Value by Type (%), 2023 VS 2030
6.5.3 China Clinical Treatment for Covid-19 Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Clinical Treatment for Covid-19 Sales Value, 2019-2030
6.6.2 Japan Clinical Treatment for Covid-19 Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Clinical Treatment for Covid-19 Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Clinical Treatment for Covid-19 Sales Value, 2019-2030
6.7.2 South Korea Clinical Treatment for Covid-19 Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Clinical Treatment for Covid-19 Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Clinical Treatment for Covid-19 Sales Value, 2019-2030
6.8.2 Southeast Asia Clinical Treatment for Covid-19 Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Clinical Treatment for Covid-19 Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Clinical Treatment for Covid-19 Sales Value, 2019-2030
6.9.2 India Clinical Treatment for Covid-19 Sales Value by Type (%), 2023 VS 2030
6.9.3 India Clinical Treatment for Covid-19 Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Applied DNA Sciences, Inc
7.1.1 Applied DNA Sciences, Inc Profile
7.1.2 Applied DNA Sciences, Inc Main Business
7.1.3 Applied DNA Sciences, Inc Clinical Treatment for Covid-19 Products, Services and Solutions
7.1.4 Applied DNA Sciences, Inc Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.1.5 Applied DNA Sciences, Inc Recent Developments
7.2 Codagenix
7.2.1 Codagenix Profile
7.2.2 Codagenix Main Business
7.2.3 Codagenix Clinical Treatment for Covid-19 Products, Services and Solutions
7.2.4 Codagenix Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.2.5 Codagenix Recent Developments
7.3 GeoVax Labs, Inc.
7.3.1 GeoVax Labs, Inc. Profile
7.3.2 GeoVax Labs, Inc. Main Business
7.3.3 GeoVax Labs, Inc. Clinical Treatment for Covid-19 Products, Services and Solutions
7.3.4 GeoVax Labs, Inc. Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.3.5 Takis Biotech Recent Developments
7.4 Takis Biotech
7.4.1 Takis Biotech Profile
7.4.2 Takis Biotech Main Business
7.4.3 Takis Biotech Clinical Treatment for Covid-19 Products, Services and Solutions
7.4.4 Takis Biotech Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.4.5 Takis Biotech Recent Developments
7.5 Evvivax
7.5.1 Evvivax Profile
7.5.2 Evvivax Main Business
7.5.3 Evvivax Clinical Treatment for Covid-19 Products, Services and Solutions
7.5.4 Evvivax Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.5.5 Evvivax Recent Developments
7.6 Zydus Cadila
7.6.1 Zydus Cadila Profile
7.6.2 Zydus Cadila Main Business
7.6.3 Zydus Cadila Clinical Treatment for Covid-19 Products, Services and Solutions
7.6.4 Zydus Cadila Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.6.5 Zydus Cadila Recent Developments
7.7 MIGAL Galilee Research Institute
7.7.1 MIGAL Galilee Research Institute Profile
7.7.2 MIGAL Galilee Research Institute Main Business
7.7.3 MIGAL Galilee Research Institute Clinical Treatment for Covid-19 Products, Services and Solutions
7.7.4 MIGAL Galilee Research Institute Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.7.5 MIGAL Galilee Research Institute Recent Developments
7.8 Generex Biotechnology Corporation
7.8.1 Generex Biotechnology Corporation Profile
7.8.2 Generex Biotechnology Corporation Main Business
7.8.3 Generex Biotechnology Corporation Clinical Treatment for Covid-19 Products, Services and Solutions
7.8.4 Generex Biotechnology Corporation Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.8.5 Generex Biotechnology Corporation Recent Developments
7.9 Moderna Therapeutics
7.9.1 Moderna Therapeutics Profile
7.9.2 Moderna Therapeutics Main Business
7.9.3 Moderna Therapeutics Clinical Treatment for Covid-19 Products, Services and Solutions
7.9.4 Moderna Therapeutics Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.9.5 Moderna Therapeutics Recent Developments
7.10 Novavax
7.10.1 Novavax Profile
7.10.2 Novavax Main Business
7.10.3 Novavax Clinical Treatment for Covid-19 Products, Services and Solutions
7.10.4 Novavax Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.10.5 Novavax Recent Developments
7.11 Bravovax
7.11.1 Bravovax Profile
7.11.2 Bravovax Main Business
7.11.3 Bravovax Clinical Treatment for Covid-19 Products, Services and Solutions
7.11.4 Bravovax Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.11.5 Bravovax Recent Developments
7.12 Ascletis Pharma
7.12.1 Ascletis Pharma Profile
7.12.2 Ascletis Pharma Main Business
7.12.3 Ascletis Pharma Clinical Treatment for Covid-19 Products, Services and Solutions
7.12.4 Ascletis Pharma Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.12.5 Ascletis Pharma Recent Developments
7.13 Janssen Pharmaceuticals
7.13.1 Janssen Pharmaceuticals Profile
7.13.2 Janssen Pharmaceuticals Main Business
7.13.3 Janssen Pharmaceuticals Clinical Treatment for Covid-19 Products, Services and Solutions
7.13.4 Janssen Pharmaceuticals Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.13.5 Janssen Pharmaceuticals Recent Developments
7.14 Altimmune
7.14.1 Altimmune Profile
7.14.2 Altimmune Main Business
7.14.3 Altimmune Clinical Treatment for Covid-19 Products, Services and Solutions
7.14.4 Altimmune Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.14.5 Altimmune Recent Developments
7.15 Greffex Inc.
7.15.1 Greffex Inc. Profile
7.15.2 Greffex Inc. Main Business
7.15.3 Greffex Inc. Clinical Treatment for Covid-19 Products, Services and Solutions
7.15.4 Greffex Inc. Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.15.5 Greffex Inc. Recent Developments
7.16 CanSino Biologics, Inc.
7.16.1 CanSino Biologics, Inc. Profile
7.16.2 CanSino Biologics, Inc. Main Business
7.16.3 CanSino Biologics, Inc. Clinical Treatment for Covid-19 Products, Services and Solutions
7.16.4 CanSino Biologics, Inc. Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.16.5 CanSino Biologics, Inc. Recent Developments
7.17 ExpreS2ion Biotechnologies ApS
7.17.1 ExpreS2ion Biotechnologies ApS Profile
7.17.2 ExpreS2ion Biotechnologies ApS Main Business
7.17.3 ExpreS2ion Biotechnologies ApS Clinical Treatment for Covid-19 Products, Services and Solutions
7.17.4 ExpreS2ion Biotechnologies ApS Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.17.5 ExpreS2ion Biotechnologies ApS Recent Developments
7.18 Clover Biopharmaceuticals
7.18.1 Clover Biopharmaceuticals Profile
7.18.2 Clover Biopharmaceuticals Main Business
7.18.3 Clover Biopharmaceuticals Clinical Treatment for Covid-19 Products, Services and Solutions
7.18.4 Clover Biopharmaceuticals Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.18.5 Clover Biopharmaceuticals Recent Developments
7.19 Vaxil Bio Ltd.
7.19.1 Vaxil Bio Ltd. Profile
7.19.2 Vaxil Bio Ltd. Main Business
7.19.3 Vaxil Bio Ltd. Clinical Treatment for Covid-19 Products, Services and Solutions
7.19.4 Vaxil Bio Ltd. Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.19.5 Vaxil Bio Ltd. Recent Developments
7.20 iBio Pharma Inc
7.20.1 iBio Pharma Inc Profile
7.20.2 iBio Pharma Inc Main Business
7.20.3 iBio Pharma Inc Clinical Treatment for Covid-19 Products, Services and Solutions
7.20.4 iBio Pharma Inc Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.20.5 iBio Pharma Inc Recent Developments
7.21 Tonix Pharmaceuticals
7.21.1 Tonix Pharmaceuticals Profile
7.21.2 Tonix Pharmaceuticals Main Business
7.21.3 Tonix Pharmaceuticals Clinical Treatment for Covid-19 Products, Services and Solutions
7.21.4 Tonix Pharmaceuticals Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.21.5 Tonix Pharmaceuticals Recent Developments
7.22 Curevac
7.22.1 Curevac Profile
7.22.2 Curevac Main Business
7.22.3 Curevac Clinical Treatment for Covid-19 Products, Services and Solutions
7.22.4 Curevac Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.22.5 Curevac Recent Developments
7.23 ImmunoPrecise
7.23.1 ImmunoPrecise Profile
7.23.2 ImmunoPrecise Main Business
7.23.3 ImmunoPrecise Clinical Treatment for Covid-19 Products, Services and Solutions
7.23.4 ImmunoPrecise Clinical Treatment for Covid-19 Revenue (US$ Million) & (2019-2024)
7.23.5 ImmunoPrecise Recent Developments
8 Industry Chain Analysis
8.1 Clinical Treatment for Covid-19 Industrial Chain
8.2 Clinical Treatment for Covid-19 Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Clinical Treatment for Covid-19 Sales Model
8.5.2 Sales Channel
8.5.3 Clinical Treatment for Covid-19 Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Applied DNA Sciences, Inc
Codagenix
GeoVax Labs, Inc.
Takis Biotech
Evvivax
Zydus Cadila
MIGAL Galilee Research Institute
Generex Biotechnology Corporation
Moderna Therapeutics
Novavax
Bravovax
Ascletis Pharma
Janssen Pharmaceuticals
Altimmune
Greffex Inc.
CanSino Biologics, Inc.
ExpreS2ion Biotechnologies ApS
Clover Biopharmaceuticals
Vaxil Bio Ltd.
iBio Pharma Inc
Tonix Pharmaceuticals
Curevac
ImmunoPrecise

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.